|
|
| (10 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt) |
| Zeile 1: |
Zeile 1: |
| | {{pnc}} | | {{pnc}} |
| | + | {{ft|X}} |
| | *'''[[Diagnosis (Laboratory other parameters)]]''' | | *'''[[Diagnosis (Laboratory other parameters)]]''' |
| | + | *'''[[Dx multi-virus]]''' |
| | *'''[[Dx PCR]]''' | | *'''[[Dx PCR]]''' |
| | *'''[[Dx Antigen]]''' | | *'''[[Dx Antigen]]''' |
| Zeile 10: |
Zeile 12: |
| | | | |
| | ---- | | ---- |
| − | {{tp|p=32077933|t=ä. ...Why Partnership between Clinical Laboratories, Public Health Agencies, and Industry Is Essential to Control the Outbreak |pdf=|usr=}}
| |
| − | {{tp|p=32353116|t=ä. Modeling SARS-CoV-2 positivity using laboratory data: timing is everything |pdf=|usr=}}
| |
| − | {{tp|p=32306042|t=ä. Testing for SARS-CoV-2: Can We Stop at Two?|pdf=|usr=}}
| |
| − | {{tp|p=32156101|t=2020. Development of a Laboratory-safe and Low-cost Detection Protocol for SARS-CoV-2 of the Coronavirus Disease 2019 (COVID-19) |pdf=|usr=}}
| |
| − | {{tp|p=32361322|t=2020. Interpret with caution: An evaluation of the commercial AusDiagnostics versus in-house developed assays for the detection of SARS-CoV-2 virus |pdf=|usr=}}
| |
| − | {{tp|p=32378843|t=2020. Akutt lungesviktsyndrom hos covid-19-pasient med negative nasofarynksprover |pdf=|usr=}}
| |
| − | {{tp|p=32403009|t=2020. Five-minute point-of-care testing for SARS-CoV-2: Not there yet |pdf=|usr=}}
| |
| − | {{tp|p=32372836|t=2020. The problems with so-called immunity tests |pdf=|usr=}}
| |
| − | {{tp|p=32475012|t=2020. Testing for SARS-CoV-2: the day the world turned its attention to the clinical laboratory.|pdf=|usr=007}}
| |
| − | {{tp|p=32320539|t=2020. La Asociacion Catalana de Salud Laboral (@SCSL) ante el gran reto de la COVID-19.|pdf=|usr=007}}
| |
| − | {{tp|p=32469511|t=2020. Virus Detection: What Were We Doing before COVID-19 Changed the World?|pdf=|usr=008}}
| |
| − | {{tp|p=32395391|t=2020. Development of a rapid test kit for SARS-CoV-2: an example of product design.|pdf=|usr=008}}
| |
| − | {{tp|p=32490854|t=2020. A novel liquid biopsy-based approach for highly specific cancer diagnostics: mitigating false responses in assaying patient plasma-derived circulating microRNAs through combined SERS and plasmon-enhanced fluorescence analyses.|pdf=|usr=008}}
| |
| − | {{tp|p=32452225|t=2020. Nasopharyngeal swab or clinical-radiological evidence: the dark side of the moon for cancer patients in the COVID-19 era.|pdf=|usr=008}}
| |
| − | {{tp|p=32504943|t=2020. The utility of beta-2-microglobulin testing as a human cellular control in COVID-19 testing.|pdf=|usr=008}}
| |
| − | {{tp|p=32473233|t=2020. Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive.|pdf=|usr=008}}
| |
| − | {{tp|p=32496708|t=2020. COVID-19 : quelle place, aujourd'hui, pour les tests serologiques ?|pdf=|usr=008}}
| |
